Oviva

What they do

Oviva is a leading European provider of digital care for weight-related and chronic illnesses. More than 200 million adults live with obesity and related chronic illnesses in Europe, presenting a multi-billion-dollar challenge which costs European countries the equivalent of over 1.5 percent of GDP each year. Healthcare systems are strained, and significant clinician shortages and a lack of access to in-person care further exacerbate the issue. Oviva addresses this by offering an evidence-based, digital solution which is well integrated within national reimbursement frameworks and physician workflows.

• The company presents a rare win-win-win opportunity:
• Better patient outcomes
• Meaningful time savings for physicians
• Lower costs along with productivity gains for health system

Oviva’s patient-facing technology paired with multidisciplinary care teams help patients achieve sustainable, best-in-class outcomes. Its AI-enabled platform personalizes support for patients and allows clinicians to focus more on real patient impact and reaching more people. The programs are free of charge for patients given the company’s full reimbursement status in its core markets: Germany, the UK, and Switzerland.

Why Kinnevik invested in Oviva

Founded by Kai Eberhardt, Ph.D., and Manuel Baumann, Oviva has found incredibly strong product market fit. The company has impressed us with their clinical rigor, disciplined execution at scale, and a genuine commitment to impacting patients and health systems for the better. Oviva’s approach has been validated by more than 90 peer-reviewed studies, and they are delivering exceptional results which underscore the scalability and durability of its product and business model:

• Supported more than one million patients to date
• Tripled new patient intake over the past two years
• Achieved cash-flow profitability in 2025

The investment builds on Kinnevik’s extensive experience in scaling technology-enabled healthcare companies, including backing one of the first digital chronic care platforms in the US through IPO and investing in the evolving weight-management medication landscape. 

To continue to create value, Oviva focuses on:

• Meeting the rising demand for reimbursed digital healthcare
• Expanding into chronic indications, including hypertension and type 2 diabetes, to help prevent and manage costly comorbidities
• Advancing its AI-powered tools to better support patients and clinicians
• Entering into new geographical markets in Europe